The latest news:

• CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence         This study shows that Optune should be continued after the first recurrence, and use it in addition to a second line therapy.  Patients who had a recurrence and remained on Optune therapy did 31% better than those that discontinued Optune.
  



• Survey on the use of animals in brain cancer research         We know this is a a controversial and emotional issue but we need to know your thoughts on the matter. Please fill out the survey.
  

BrainTumor Co-Payment Assistance Program Status:

• CLOSED to new applicants